A milestone for the therapeutic EV field: FDA approves Ryoncil, an allogeneic bone marrow-derived mesenchymal stromal cell therapy
Extracellular Vesicles and Circulating Nucleic Acids · 25.03.2025 · 6 (1) · 183-90
DOI: 10.20517/evcna.2025.02 ↗Kurz gefasst
Fachartikel in der Zeitschrift Extracellular Vesicles and Circulating Nucleic Acids, online erschienen am 25.03.2025. Verfasst von Bernd Giebel. Beteiligte Einrichtung: Institute for Transfusion Medicine, University Hospital Essen, University of Duisburg-Essen, Essen 45147, Germany. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Small extracellular vesicles (sEVs) derived from mesenchymal stromal cells (MSCs) hold substantial promise for therapeutic applications, including immune modulation and tissue regeneration. However, challenges such as batch-to-batch variability, donor material diversity, and the lack of standardized potency testing remain significant barriers to clinical translation. The recent U.S. Food and Drug Administration (FDA) approval of Ryoncil (remestemcel-L) for steroid-refractory acute graft-versus-host disease (aGvHD) in pediatric patients represents a crucial milestone for MSC-based therapies, offering also valuable insights for the development of MSC-EV therapies. This approval highlights the critical need to address variability and standardization issues in MSC products. Strategies like immortalizing MSCs and expanding them clonally can improve scalability, consistency, and overcome limitations inherent to cellular MSC therapies. With the FDA’s decision signaling significant progress, optimizing MSC expansion protocols and refining potency testing methods will be crucial for advancing MSC-EVs as a viable therapeutic option, overcoming current challenges, and expanding clinical applications.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute for Transfusion Medicine, University Hospital Essen, University of Duisburg-Essen, Essen 45147, Germany.
Zitieren
APA
Giebel, B. (2025). A milestone for the therapeutic EV field: FDA approves Ryoncil, an allogeneic bone marrow-derived mesenchymal stromal cell therapy. Extracellular Vesicles and Circulating Nucleic Acids, 6(1), 183-90. https://doi.org/10.20517/evcna.2025.02
Vancouver
Giebel B. A milestone for the therapeutic EV field: FDA approves Ryoncil, an allogeneic bone marrow-derived mesenchymal stromal cell therapy. Extracellular Vesicles and Circulating Nucleic Acids. 2025;6(1):183-90. doi:10.20517/evcna.2025.02
BibTeX
@article{Giebel2025,
author = {Giebel, Bernd},
title = {A milestone for the therapeutic EV field: FDA approves Ryoncil, an allogeneic bone marrow-derived mesenchymal stromal cell therapy},
journal = {Extracellular Vesicles and Circulating Nucleic Acids},
year = {2025},
volume = {6},
number = {1},
pages = {183--90},
doi = {10.20517/evcna.2025.02}
}
EUVIMED